Analytical Data
-
Gene name
ACE2
- Application
-
Alternative Names
ACEH; ACEII; ACE-II; Peptidyl-Dipeptidase A; ACE-related carboxypeptidase; Angiotensin-converting enzyme homolog; Metalloprotease MPROT15
-
Species
Mouse
-
Source
HEK293
-
Tag
N-His
-
Purity
Greater than 95% as determined by SDS-PAGE.
-
Uniprot
Q8R0I0
-
Expression Region
Gln18~Thr740
-
Molecular Weight
87kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Angiotensin-converting enzyme 2 (ACE2) is a crucial enzyme in the renin-angiotensin system, which plays a significant role in regulating blood pressure and maintaining fluid balance. Beyond its physiological functions, ACE2 has gained prominence in recent years due to its role as the primary receptor for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for COVID-19. The binding of the viral spike protein to ACE2 facilitates viral entry into host cells, making ACE2 a target for therapeutic intervention and vaccine development. Researchers have been focusing on recombinant ACE2 proteins, which are engineered versions of the native enzyme, as potential treatments for COVID-19. These recombinant proteins can act as decoys that bind to the virus, thereby preventing it from attaching to human cells. The engineering of ACE2 has allowed for modifications that enhance its stability, binding affinity, and therapeutic potential. Additionally, studies have explored the systemic effects of ACE2, suggesting that enhancing its activity can mitigate acute lung injury and promote cardiovascular health. The ongoing research into ACE2 recombinant proteins is crucial for developing new strategies to combat COVID-19 and understanding their broader implications in cardiovascular and respiratory diseases.
